Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.

Valneva at a glance

Commercial vaccines for travelers

€m

Total revenues in 2020

Unique vaccine development programs

Integrated

differentiated clinical and pre-clinical assets

robust commercial portfolio

Focused

on prevention of infectious diseases with significant unmet medical need

~700

employees in six countries